Linasmart 5 Tablet contains Linagliptin 5mg, an oral antihyperglycemic agent belonging to the dipeptidyl peptidase-4 (DPP-4) inhibitor class, indicated for the management of type 2 diabetes mellitus. Linagliptin works by selectively inhibiting the DPP-4 enzyme, thereby increasing the levels of incretin hormones such as GLP-1 and GIP. These hormones enhance glucose-dependent insulin secretion and suppress glucagon release, leading to improved glycemic control. Linasmart 5 is typically prescribed as monotherapy or in combination with other antidiabetic agents, including metformin, sulfonylureas, or insulin, to achieve optimal blood glucose regulation. The medication is administered orally, once daily, with or without food. Clinical studies have demonstrated that Linagliptin effectively lowers HbA1c levels with a low risk of hypoglycemia and is weight neutral. It is generally well tolerated, with common adverse effects including nasopharyngitis, headache, and upper respiratory tract infections. Caution is advised in patients with renal or hepatic impairment, although dose adjustment is generally not required. Linasmart 5 should be used as part of a comprehensive diabetes management plan, including diet and exercise, under medical supervision to reduce the risk of diabetes-related complications.